Cetuximab Given Every 2 Weeks plus Irinotecan Is an Active and Safe Option for Previously Treated Patients with Metastatic Colorectal Cancer
作者： José-María Roca , Vicente Alonso , Carles Pericay , Pilar Escudero , Antonieta Salud
DOI: 10.1159/000313527
关键词:
摘要: Background: We gathered data from multiple institutions on the cetuximab regimen of patients with metastatic colorectal cancer. Methods: 126 19 cent
karger.com
sci-hub.se 参考文章(19)
Mario Scartozzi, Italo Bearzi, Rossana Berardi, Alessandra Mandolesi, Guidalberto Fabris, Stefano Cascinu, Epidermal Growth Factor Receptor (EGFR) Status in Primary Colorectal Tumors Does Not Correlate With EGFR Expression in Related Metastatic Sites: Implications for Treatment With EGFR-Targeted Monoclonal Antibodies Journal of Clinical Oncology. ,vol. 22, pp. 4772- 4778 ,(2004) , 10.1200/JCO.2004.00.117
Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, Jerzy Zaluski, Chung-Rong Chang Chien, Anatoly Makhson, Geert D'Haens, Tamás Pintér, Robert Lim, György Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Johannes Nippgen, Philippe Rougier, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England Journal of Medicine. ,vol. 360, pp. 1408- 1417 ,(2009) , 10.1056/NEJMOA0805019
Daniel Vallböhmer, Wu Zhang, Michael Gordon, Dong Yun Yang, Jim Yun, Oliver A. Press, Katrin E. Rhodes, Andy E. Sherrod, Syma Iqbal, Kathleen D. Danenberg, Susan Groshen, Heinz-Josef Lenz, Molecular Determinants of Cetuximab Efficacy Journal of Clinical Oncology. ,vol. 23, pp. 3536- 3544 ,(2005) , 10.1200/JCO.2005.09.100
P. Pfeiffer, D. Nielsen, J. Bjerregaard, C. Qvortrup, M. Yilmaz, B. Jensen, Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil Annals of Oncology. ,vol. 19, pp. 1141- 1145 ,(2008) , 10.1093/ANNONC/MDN020
Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, Jantien Wanders, Richard S. Kaplan, Larry Rubinstein, Jaap Verweij, Martine Van Glabbeke, Allan T. van Oosterom, Michaele C. Christian, Steve G. Gwyther, New Guidelines to Evaluate the Response to Treatment in Solid Tumors JNCI: Journal of the National Cancer Institute. ,vol. 92, pp. 205- 216 ,(2000) , 10.1093/JNCI/92.3.205
David Cunningham, Yves Humblet, Salvatore Siena, David Khayat, Harry Bleiberg, Armando Santoro, Danny Bets, Matthias Mueser, Andreas Harstrick, Chris Verslype, Ian Chau, Eric Van Cutsem, None, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. The New England Journal of Medicine. ,vol. 351, pp. 337- 345 ,(2004) , 10.1056/NEJMOA033025
Carsten Bokemeyer, Igor Bondarenko, Anatoly Makhson, Joerg T. Hartmann, Jorge Aparicio, Filippo de Braud, Serban Donea, Heinz Ludwig, Gunter Schuch, Christopher Stroh, Anja H. Loos, Angela Zubel, Piotr Koralewski, Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 27, pp. 663- 671 ,(2009) , 10.1200/JCO.2008.20.8397
Christos S. Karapetis, Shirin Khambata-Ford, Derek J. Jonker, Chris J. O'Callaghan, Dongsheng Tu, Niall C. Tebbutt, R. John Simes, Haji Chalchal, Jeremy D. Shapiro, Sonia Robitaille, Timothy J. Price, Lois Shepherd, Heather-Jane Au, Christiane Langer, Malcolm J. Moore, John R. Zalcberg, K-ras mutations and benefit from cetuximab in advanced colorectal cancer. The New England Journal of Medicine. ,vol. 359, pp. 1757- 1765 ,(2008) , 10.1056/NEJMOA0804385
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
Ki Young Chung, Jinru Shia, Nancy E. Kemeny, Manish Shah, Gary K. Schwartz, Archie Tse, Audrey Hamilton, Dorothy Pan, Deborah Schrag, Lawrence Schwartz, David S. Klimstra, Daniel Fridman, David P. Kelsen, Leonard B. Saltz, Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry Journal of Clinical Oncology. ,vol. 23, pp. 1803- 1810 ,(2005) , 10.1200/JCO.2005.08.037